InMed Pharmaceuticals IncNASDAQ:INMNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE4.7500
- TODAY'S CHANGE (%)0.1000 (2.1505%)
- Bid / Lots4.5700/ 2
- Ask / Lots4.7500/ 10
- Open / Previous Close4.6700 / 4.6500
- Day Range
- 52 Week Range
- Volume30,223
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | INM |
|---|---|---|
| 09:51 ET | 182 | 4.67 |
| 09:53 ET | 1200 | 4.79 |
| 09:55 ET | 2478 | 4.76 |
| 09:57 ET | 2288 | 4.61 |
| 10:22 ET | 150 | 4.7554 |
| 10:31 ET | 450 | 4.7435 |
| 11:07 ET | 500 | 4.97 |
| 11:09 ET | 227 | 4.73 |
| 11:41 ET | 156 | 4.62 |
| 11:48 ET | 1500 | 4.61 |
| 12:01 ET | 200 | 4.78 |
| 12:12 ET | 100 | 4.78 |
| 12:17 ET | 1311 | 4.5929 |
| 12:24 ET | 725 | 4.7811 |
| 12:26 ET | 460 | 4.72 |
| 12:28 ET | 158 | 4.6764 |
| 12:53 ET | 146 | 4.96 |
| 12:55 ET | 100 | 4.87 |
| 01:40 ET | 500 | 4.591 |
| 01:42 ET | 100 | 4.6065 |
| 02:03 ET | 200 | 4.84 |
| 02:07 ET | 108 | 4.7125 |
| 02:34 ET | 100 | 4.75 |
Nov 19, 2024
InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System, from 7:32AM ET on Tuesday Nov 19, 2024 by Dow Jones
7:32AM ET on Tuesday Nov 19, 2024 by Dow Jones
Nov 14, 2024
InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update, from 4:46PM ET on Thursday Nov 14, 2024 by Dow Jones
4:46PM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 8, 2024
InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules, from 4:46PM ET on Friday Nov 08, 2024 by Dow Jones
4:46PM ET on Friday Nov 08, 2024 by Dow Jones
Nov 5, 2024
Oct 28, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
InMed Pharmaceuticals Inc | 3.3M | -0.1x | --- |
Stemtech Corp | 6.8M | -1.0x | --- |
Plus Therapeutics Inc | 7.1M | -0.5x | --- |
Kineta Inc | 5.5M | -0.3x | --- |
Athersys Inc | 60.0 | 0.0x | --- |
Petros Pharmaceuticals Inc | 2.6M | -0.1x | --- |
Company Information
InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
Contact Information
- Headquarters
- 1445-885 West Georgia St.VANCOUVER, BC, Canada V6C 3E8
- Phone
- 604-669-7207
- Fax
- 778-945-6800
Executives
- Independent Chairman of the Board
- Andrew Hull
- President, Chief Executive Officer, Director
- Eric Adams
- Chief Financial Officer, Corporate Secretary
- N. Netta Jagpal
- Chief Operating Officer
- Michael Woudenberg
- Senior Vice President - Preclinical Research and Development
- Eric Hsu
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.3M |
|---|---|
Revenue (TTM) | $5.0M |
Shares Outstanding | 718.1K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.69 |
EPS | $-65.44 |
Book Value | $20.64 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 0.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -146.32% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
